September 25, 2007 - According to a study published in the October issue of Radiology, researchers using functional magnetic resonance imaging (fMRI) have found a new marker that may aid in early diagnosis of Alzheimer’s disease.

“The findings of this study implicate a potential functional, rather than structural, brain marker—separate from atrophy—that may help enhance diagnosis and treatment monitoring of Alzheimer’s patients,” said the study’s lead author, Jeffrey R. Petrella, M.D., associate professor of radiology at Duke University Medical Center in Durham, N.C.

Among the earliest known changes to the brain in Alzheimer’s disease are episodic memory deficits and structural changes in the medial temporal lobe (MTL). For the study, Dr. Petrella and colleagues set out to identify brain regions in which changes in activation took place during a memory task and to correlate these changes with the degree of memory impairment present in patients with Alzheimer’s disease or mild cognitive impairment.

The researchers studied 13 patients with mild Alzheimer’s disease, 34 patients with mild cognitive impairment and 28 healthy controls. The study group contained 37 men and 38 women with a mean age of 72.9 years. After completing standard neuropsychological testing, the study participants were monitored with fMRI while performing a face-name associative memory task.

While some areas of the brain activate, or turn on their activity, when a person tries to remember something, other areas deactivate, or suppress their activity. Results from this study showed that along the spectrum from healthy people at low risk, to people with mild memory problems, to patients with Alzheimer’s disease, there was increasingly impaired activation in the MTL, an area of the brain associated with episodic memory that normally turns on during a memory task. More surprising, however, was increasingly impaired deactivation in the posteromedial cortices (PMC), an area recently implicated with personal memory that normally suppresses its activity during a memory task. The magnitude of deactivation in the PMC was closely related to the level of memory impairment in the patients and significantly correlated with their neuropsychological testing scores.

While previous studies have suggested that MTL activation may be a possible marker of Alzheimer’s, based on the findings, Dr. Petrella and colleagues concluded that, compared to activation in the MTL, deactivation in the PMC may represent a more sensitive marker of early Alzheimer’s disease.

For more information: RSNA.org/radiologyjnl


Related Content

News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
News | Archive Cloud Storage

Nov. 30, 2025 — Gradient Health, Inc. has released Atlas 2, a major upgrade to its self-service medical imaging data ...

Time December 01, 2025
arrow
News | Artificial Intelligence

Nov. 24, 2025 — Siemens Healthineers is launching artificial intelligence-enabled services to help healthcare providers ...

Time November 24, 2025
arrow
News | Artificial Intelligence

Nov. 20, 2025 — Aidoc has announced a collaboration with AdventHealth to launch one of the largest imaging AI ...

Time November 21, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Nov. 10, 2025 — There has been substantial progress in the past few years in the field of MRI in general and remote MR ...

Time November 11, 2025
arrow
News | Contrast Media

Nov. 10, 2025 — Scientists at the University of Birmingham have developed a new class of MRI contrast agents – improving ...

Time November 10, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Subscribe Now